Arthaud

To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors

Retrieved on: 
Monday, July 6, 2020
Cellectis, Board of directors, Arthaud, Business, Companies, Articles

Calyxts Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately.

Key Points: 
  • Calyxts Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately.
  • Additionally, Calyxts Board of Directors appointed Laurent Arthaud, Cellectis Board member, as a Cellectis designated Director, effective immediately.
  • In addition, the Calyxt Board of Directors appointed Laurent Arthaud, a member of Cellectis Board of Directors since 2011, as Director.
  • Mr. Arthaud served as a member of Calyxts Board of Directors until May 2019 and is a member of Cellectis Board of Directors since 2011.

SparingVision to Attend the Biotech Showcase During JPMorgan Conference in San Francisco, Announces the Appointment of Stephane Boissel as New Chairman of the Board

Retrieved on: 
Wednesday, January 15, 2020
Biotechnology, Genetics, Optical, Health, Sangamo Therapeutics, Arthaud, Board of directors, Business, Articles, Companies

The company announces today that Stephane Boissel is joining its Board of Directors as Chairman of the Board.

Key Points: 
  • The company announces today that Stephane Boissel is joining its Board of Directors as Chairman of the Board.
  • Stephane Boissel is set to replace Laurent Arthaud, a representative of Bpifrance, who will remain a Board Member.
  • Stephane Boissel is Executive Vice President, Corporate Strategy at Sangamo Therapeutics, a gene-editing company listed on the NASDAQ.
  • I wish to thank the Board of Directors and Florence Allouche for their trust, said Stephane Boissel, new Chairman of the Board at SparingVision.